GLUE logo

Monte Rosa Therapeutics, Inc. (GLUE)

Profile

Full Name

Monte Rosa Therapeutics, Inc.

Ticker

NASDAQ: GLUE

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 24, 2021

Indexes

Not included

Website

https://www.monterosatx.com

Employees

142

Key Details

Price

$12.07(-6.07%)

Market Cap

$745.44M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$75.62M(100.00% YoY)

Annual EPS

-$0.98(62.65% YoY)

PE Ratio

35.17

Next earnings date

Nov 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $12.07
    GLUE price is $12.07

    30-Day Relative Volume

    0.81
    GLUE 30-day relative volume is 0.81

    Price Performance

    Price Most Recent Change

    -6.07%
    GLUE price was down -6.07% on Nov 3, 2025

    Price YTD Change

    +73.92%
    GLUE price is up +73.92% since January 1st

    Price 1-Year Change

    +35.62%
    GLUE price is up +35.62% year-on-year

    Price 3-Year Change

    +46.13%
    GLUE price is up +46.13% over the past 3 years

    Price Range

    Price All-Time High

    $45.56
    GLUE price is currently -73.51% below its historical high of $45.56

    Price 3-Year Low

    $2.44
    GLUE price is currently +394.67% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market Cap

    $745.44M
    GLUE market cap is $745.44 million

    Market Cap 3-Year Change

    +86.56%
    GLUE market cap is up +86.56% over the past 3 years

    Market Cap All-Time High

    $1.96B
    GLUE market cap is currently -61.92% below its historical high of $1.96 billion

    Market Cap Sector Percentile

    67.36%
    GLUE market cap is higher than 67.36% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +0.62%
    GLUE shares outstanding is up +0.62% year-on-year

    Shares Outstanding 3-Year Change

    +27.67%
    GLUE shares outstanding is up +27.67% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    1.04
    GLUE beta is 1.04

    200-day SMA

    $5.81
    GLUE price is currently +107.58% above its 200-day simple moving average

    50-day SMA

    $7.82
    GLUE price is currently +54.41% above its 50-day simple moving average

    14-Day RSI

    67.28
    GLUE 14-day relative strength index is 67.28

    Volume

    0.81
    GLUE 30-day relative volume is 0.81

    ATR

    $0.79
    GLUE average true range is $0.79

    10-day Historical Volatility

    93.16%
    GLUE 10-day historical volatility is 93.16%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $75.62M
    GLUE annual revenue is $75.62 million

    Revenue Analysts Estimate

    $141.56M
    GLUE annual revenue is currently -46.58% lower than the consensus analysts' forecast

    Revenue 1-Year Change

    +100%
    GLUE annual revenue is up +100% year-on-year

    Revenue Sector Percentile

    66.16%
    GLUE annual revenue is higher than 66.16% of companies in Healthcare sector

    EPS

    EPS

    -$0.98
    GLUE annual earnings per share is -$0.98

    EPS Analysts Estimate

    -$0.03
    GLUE annual earnings per share is currently -2776.02% lower than the consensus analysts' forecast

    EPS 1-Year Change

    +62.65%
    GLUE annual earnings per share is up +62.65% year-on-year

    EPS Sector Percentile

    56.35%
    GLUE annual earnings per share is higher than 56.35% of companies in Healthcare sector

    Profit

    Gross Profit

    $67.50M
    GLUE annual gross profit is $67.50 million

    Gross Margin

    89.26%
    GLUE annual gross profit margin is 89.26%

    Operating Profit

    -$81.11M
    GLUE annual operating income is -$81.11 million

    Operating Margin

    -107.26%
    GLUE annual operating profit margin is -107.26%

    Net Income

    -$72.70M
    GLUE annual net profit is -$72.70 million

    Net Margin

    -96.14%
    GLUE annual net profit margin is -96.14%

    Expenses

    Total Expenses

    $156.73M
    GLUE annual total expenses is $156.73 million

    Operating Expenses

    $156.73M
    GLUE annual total operating expenses is $156.73 million

    Cost Of Goods Sold

    $8.12M
    GLUE annual cost of goods sold is $8.12 million

    Selling, General & Administrative Expenses

    $35.17M
    GLUE annual SG&A is $35.17 million

    Depreciation & Amortization

    $8.12M
    GLUE annual D&A is $8.12 million

    Interest Expense

    $0.00
    GLUE annual interest expense is $0.00

    Income Tax

    $2.57M
    GLUE annual income tax is $2.57 million

    EBIT & EBITDA

    EBIT

    -$81.11M
    GLUE annual earnings before interest & taxes is -$81.11 million

    EBITDA

    -$72.99M
    GLUE annual EBITDA is -$72.99 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total Assets

    $438.73M
    GLUE annual total assets is $438.73 million

    Non Current Assets

    $61.29M
    GLUE annual long term assets is $61.29 million

    Current Assets

    $377.44M
    GLUE annual total current assets is $377.44 million

    Cash and Cash Equivalents

    $224.25M
    GLUE annual cash & cash equivalents is $224.25 million

    Accounts Receivable

    -
    GLUE annual accounts receivable value is unknown

    Inventory

    $0.00
    GLUE annual inventory is $0.00

    Liabilities

    Total Liabilities

    $215.80M
    GLUE annual total liabilities is $215.80 million

    Long Term Liabilities

    $58.85M
    GLUE annual total long term liabilities is $58.85 million

    Current Liabilities

    $156.95M
    GLUE annual current liabilities is $156.95 million

    Accounts Payable

    $17.21M
    GLUE annual accounts payable is $17.21 million

    Debt

    Total Debt

    $42.72M
    GLUE annual total debt is $42.72 million

    Total Debt 1-Year Change

    -7.22%
    GLUE annual total debt is down -7.22% year-on-year

    Long Term Debt

    $39.00M
    GLUE annual long term debt is $39.00 million

    Short Term Debt

    $3.71M
    GLUE annual short term debt is $3.71 million

    Equity & Capital

    Shareholders Equity

    $222.94M
    GLUE annual stockholders equity is $222.94 million

    Book Value

    $222.94M
    GLUE annual book value is $222.94 million

    Retained Earnings

    -$438.59M
    GLUE annual retained earnings is -$438.59 million

    Working Capital

    $220.49M
    GLUE annual working capital is $220.49 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash From Operations

    $42.00M
    GLUE annual cash from operations is $42.00 million

    Cash From Operations 1-Year Change

    +195.88%
    GLUE annual cash from operations is up +195.88% year-on-year

    Cash From Investing

    -$44.45M
    GLUE annual cash from investing is -$44.45 million

    Cash From Investing 1-Year Change

    -150.06%
    GLUE annual cash from investing is down -150.06% year-on-year

    Cash From Financing

    $98.89M
    GLUE annual cash from financing is $98.89 million

    Cash From Financing 1-Year Change

    +259.71%
    GLUE annual cash from financing is up +259.71% year-on-year

    CAPEX

    CAPEX

    $3.99M
    GLUE annual capital expenditures is $3.99 million

    CAPEX 1-Year Change

    -79.06%
    GLUE annual capital expenditures is down -79.06% year-on-year

    Free Cash Flow

    Free Cash Flow

    $38.01M
    GLUE annual free cash flow is $38.01 million

    Free Cash Flow 1-Year Change

    +160.48%
    GLUE annual free cash flow is up +160.48% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross Margin

    89.26%
    GLUE annual gross profit margin is 89.26%

    Operating Margin

    -107.26%
    GLUE annual operating profit margin is -107.26%

    Net Margin

    -96.14%
    GLUE annual net profit margin is -96.14%

    ROA & ROE

    ROA

    -19.58%
    GLUE annual return on assets is -19.58%

    ROE

    -36.15%
    GLUE annual return on equity is -36.15%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE Ratio

    35.17
    GLUE price to earnings ratio is 35.17

    PE Ratio Sector Percentile

    66.36%
    GLUE price to earnings ratio is higher than 66.36% of companies in Healthcare sector

    PB Ratio

    PB Ratio

    2.78
    GLUE price to book ratio is 2.78

    PB Ratio Sector Percentile

    60.96%
    GLUE price to book ratio is higher than 60.96% of companies in Healthcare sector

    PS Ratio

    PS Ratio

    4.19
    GLUE price to sales ratio is 4.19

    PS Ratio Sector Percentile

    52.4%
    GLUE price to sales ratio is higher than 52.4% of companies in Healthcare sector

    Enterprise value

    Enterprise Value

    $495.97M
    GLUE enterprise value is $495.97 million

    Enterprise Value Sector Percentile

    64.07%
    GLUE enterprise value is higher than 64.07% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    21.29
    GLUE EV/EBITDA is 21.29

    EV/EBITDA Sector Percentile

    91.36%
    GLUE EV/EBITDA is higher than 91.36% of companies in Healthcare sector

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current Ratio

    2.40
    GLUE annual current ratio is 2.40

    Quick Ratio

    2.40
    GLUE annual quick ratio is 2.40

    Leverage

    Debt To Equity

    0.19
    GLUE annual debt to equity ratio is 0.19

    Interest Coverage Ratio

    -
    GLUE annual interest coverage ratio value is unknown

    Risk & Stability

    F-Score

    8
    GLUE piotroski f-score is 8

    Altman Z-Score

    0.84
    GLUE altman z-score is 0.84

    Analyst ratings

    Recent major analysts updates

    Mar 21, 25 Wells Fargo
    Equal-Weight
    Mar 21, 25 Wedbush
    Outperform
    Mar 12, 25 LifeSci Capital
    Outperform
    Dec 19, 24 Wells Fargo
    Equal-Weight
    Sep 12, 24 Wedbush
    Outperform
    Aug 12, 24 Wells Fargo
    Overweight
    Jun 28, 24 Piper Sandler
    Overweight
    May 22, 24 Wedbush
    Outperform
    Feb 15, 24 Wedbush
    Outperform
    Oct 19, 23 JP Morgan
    Overweight

    Institutional Ownership

    Screeners with GLUE included

    Growing Shares Outstanding
    US stocks
    High Piotroski score stocks
    Stocks with high beta
    Best performing stocks last month
    Most recommended stocks
    Best performing stocks last 3 months
    NASDAQ Dividend Calendar
    Stocks below analysts price target
    Healthcare sector
    • What is the ticker symbol for Monte Rosa Therapeutics, Inc.?
    • Does Monte Rosa Therapeutics, Inc. pay dividends?
    • What sector is Monte Rosa Therapeutics, Inc. in?
    • What industry is Monte Rosa Therapeutics, Inc. in?
    • What country is Monte Rosa Therapeutics, Inc. based in?
    • When did Monte Rosa Therapeutics, Inc. go public?
    • Is Monte Rosa Therapeutics, Inc. in the S&P 500?
    • Is Monte Rosa Therapeutics, Inc. in the NASDAQ 100?
    • Is Monte Rosa Therapeutics, Inc. in the Dow Jones?
    • When was Monte Rosa Therapeutics, Inc.'s last earnings report?
    • When does Monte Rosa Therapeutics, Inc. report earnings?

    What is the ticker symbol for Monte Rosa Therapeutics, Inc.?

    The ticker symbol for Monte Rosa Therapeutics, Inc. is NASDAQ:GLUE

    Does Monte Rosa Therapeutics, Inc. pay dividends?

    No, Monte Rosa Therapeutics, Inc. does not pay dividends

    What sector is Monte Rosa Therapeutics, Inc. in?

    Monte Rosa Therapeutics, Inc. is in the Healthcare sector

    What industry is Monte Rosa Therapeutics, Inc. in?

    Monte Rosa Therapeutics, Inc. is in the Biotechnology industry

    What country is Monte Rosa Therapeutics, Inc. based in?

    Monte Rosa Therapeutics, Inc. is headquartered in United States

    When did Monte Rosa Therapeutics, Inc. go public?

    Monte Rosa Therapeutics, Inc.'s initial public offering (IPO) was on June 24, 2021

    Is Monte Rosa Therapeutics, Inc. in the S&P 500?

    No, Monte Rosa Therapeutics, Inc. is not included in the S&P 500 index

    Is Monte Rosa Therapeutics, Inc. in the NASDAQ 100?

    No, Monte Rosa Therapeutics, Inc. is not included in the NASDAQ 100 index

    Is Monte Rosa Therapeutics, Inc. in the Dow Jones?

    No, Monte Rosa Therapeutics, Inc. is not included in the Dow Jones index

    When was Monte Rosa Therapeutics, Inc.'s last earnings report?

    Monte Rosa Therapeutics, Inc.'s most recent earnings report was on May 15, 2025

    When does Monte Rosa Therapeutics, Inc. report earnings?

    The next expected earnings date for Monte Rosa Therapeutics, Inc. is November 13, 2025
    On this page